NEW YORK – PierianDx will integrate the Pillar Biosciences PiVAT cancer bioinformatics pipeline into its core technology platform, the companies announced Wednesday. Under the new partnership, Pillar Bio, which has co-headquarters in Boston and Shanghai, will market PieranDx clinical genomic reports along with its own cancer profiling assays.
The integrated product will produce an "out-of-the-box" clinical genomic report specific to each assay, saving time in the process of interpreting and reporting next-generation sequencing data, according to the companies. The firms promised that the offering will be compliant with the European Union's General Data Protection Regulation (GDPR), so it can be sold globally.
"By optimizing variant filters and integrating with the PiVAT pipeline, PierianDx is streamlining interpretation and reporting, which adds substantial value for our customers," Pillar Biosciences CEO Gang Song said in a statement.
"As the market shifts to more sensitive assays in the [laboratory-developed test] space and leading assay manufacturers seek in vitro diagnostic (IVD) approval, we are committed to addressing challenges that arise from even greater complexity in the interpretation and reporting process," added Rakesh Nagarajan, founder and chief technical and visionary officer of St. Louis-based PierianDx.
Pillar Bio, which makes clinical cancer diagnostics, including NGS-based panels and related software, has a partnership with Illumina to develop IVD tests.